Search Results for: 19

ROCKVILLE, Md., March 12, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 25th Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana […]

— The University of Texas at Austin to Join in Pertussis Research Efforts — ROCKVILLE, Md. and SAN FRANCISCO, Dec. 20, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, and Intrexon Corporation, a leading synthetic biology company that utilizes its proprietary technologies to provide

— Accelerating Development of Product Candidates to Address Serious Infectious Diseases — ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, today reported financial results for the three and nine months ended September 30, 2012 and summarized operational highlights.

— Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics — ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and

— Preclinical and Clinical Programs Moving Forward — ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights. Operational Highlights Management Team –

— Gene Therapy Veteran to Enhance Company’s DNA-Based Therapeutic Development — ANN ARBOR, Mich., April 18, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Michael Kaleko, M.D., Ph.D., has joined the Company as Scientific Director. Dr. Kaleko has worked

— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported  financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics